Innovative treatments for gastrointestinal cancer! Bronger Ingham pioneered RAILR2/CDH17 dual-specific antibody BI 905711 into human clinical trials!

September 14, 2020 // -- Boehringer Ingelheim recently announced the promotion of bisceste and tetracyclytic therapeutic antibody BI 905711 to the first human clinical trial for the treatment of patients with advanced gastrointestinal (GI) cancer.
BI 905711 is a pioneering (first-in-class) two-specific, tetrically therapeutic antibody designed to simultaneously identify apoptosis-related apoptosis induces (TNF) Libids 2 (TRAILR2) and tumor cells anchor calcium mucosal protein 17 (CDH17) to activate the self-destruction (apoptosis) pathway in tumor cells expressed in RAILR2/CDH17, which is found mainly in the gastrointestinal tract.
in developing innovative, more toned therapies to address high-demand diseases, the entry of BI 905711 into Phase 1 marks an important milestone for patients with gastrointestinal cancer.
by avoiding liver toxicity common in other treatments for RAILR2, BI 905711 may provide more toned and selective treatments for patients with gastrointestinal cancer.
gastrointestinal cancer is the leading cause of cancer-related deaths worldwide.
among gastrointestinal cancers, colorectal cancer is the focus of this Phase 1 trial, the third most common cancer and the second deadliest cancer, with more than 1.8 million colorectal cancer cases and 880,000 deaths worldwide in 2018.
so far, there have been few innovative treatments for patients diagnosed with gastrointestinal malignancies, and although chemotherapy has known serious side effects, it remains a pillar of treatment.
a targeted treatment that does not require chemotherapy efficacy to provide patients with an alternative, innovative and potentially non-toxic treatment.
Norbert Kraut, head of global cancer research at Bronge Ingham,
BI 905711 (Photo: inoncology.com), said: "We are proud to be able to push BI 905711 into Phase 1 clinical trials and continue to develop our oncology pipeline to change patients' lives.
this dual-specific platform has the potential for complex mechanisms that are not available in traditional antibody forms.
"BI 905711 has shown preclinical anti-tumor activity in cancer cells expressed in total for RAILR2/CDH17," said lead researcher James Harding, M.D., of the Department of Early Drug Development and Gastrointestinal Oncology Services at Sloan-Kettering Memorial Cancer Center in New York, USA.
look forward to evaluating this molecule with Grigg Ingham in the ongoing Phase 1 study.
" Blainger Ingeham Oncology business is addressing the unsealed needs of lung and gastrointestinal cancers through cancer cell-guided preparations, immuno-oncology therapies, and their combinations.
the company has invested heavily in early research to identify unexerfed and untreated cancer pathflytes.
2019, the company advanced six molecules to its first human study, including two pioneering compounds for Wnt/beta-catenin pathfly (BI 905681) and KRAS-driven cancer (BI 1701963), demonstrating the company's long-standing commitment to leading science, improving clinical practice, and ultimately changing patients' lives to help them beat cancer.
() Original source: Boehringer Ingelheim Advanceds Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living With Gastrointestinal Cancers.